| ARCHETYPE ID | openEHR-EHR-OBSERVATION.briganti_risk_score.v0 |
|---|---|
| Concept | Briganti Risk Score |
| Description | The Briganti risk score is a score for predicting probabilities of survival, recurrence, lymph node involvement, organ-defined involvement, extracapsular extension and seminal invasion. |
| Use | Use to capture details and total scores under Briganti Risk score. |
| Purpose | Intended for recording details of Briganti Risk Score for prostate cancer. |
| References | https://www.mskcc.org/nomograms/prostate/pre-op |
| Copyright | © Clinical Models UK |
| Authors | Author name: Hildegard Franke Organisation: freshEHR Clinical Informatics Ltd. Email: hildi@freshehr.com Date originally authored: 2016-05-30 |
| Other Details Language | Author name: Hildegard Franke Organisation: freshEHR Clinical Informatics Ltd. Email: hildi@freshehr.com Date originally authored: 2016-05-30 |
| Other Details (Language Independent) |
|
| Keywords | Briganti, score, prostate, cancer, lymph, malignancy, recurrence |
| Lifecycle | in_development |
| UID | d4ecbe3e-f10d-4d92-9aea-44894954e285 |
| Language used | en |
| Citeable Identifier | 1246.145.2760 |
| Revision Number | 0.0.1-alpha |
| protocol | |
| Extension | Extension: Additional information required to capture local content or to align with other reference models/formalisms. e.g. Local information requirements or additional metadata to align with FHIR or CIMI equivalents. Include: All not explicitly excluded archetypes |
| state | |
| Confounding factors | Confounding factors: Description of any incidental factors that may have contributed to the score. |
| data | |
| Age | Age: Patient age when risk score is calculated. Allowed values: years 0 years..150 years |
| PSA level before biopsy | PSA level before biopsy: PSA level from laboratory report before the biopsy. Property: Concentration Units: 0.1..100.0 nanogm/ml Limit decimal places: 1 |
| Gleason Grade | Gleason Grade: Primary, secondary and tertiary Gleason grades and Total Gleason score. Include: All not explicitly excluded archetypes |
| Tumour Staging | Tumour Staging: Clinical tumor stage is determined by digital rectal examination and does not include stages determined by imaging studies.
What was your clinical tumor stage, using the AJCC Version 7/2010 Staging System?
Note: Although it is possible to be stage TX or stage T4, this nomogram is not applicable for these stages. Include: openEHR-EHR-CLUSTER.tnm_ |
| Positive biopsy cores | Positive biopsy cores: Number of positive cores taken during biopsy. Information on cores taken at biopsy is optional. The nomogram can provide predictions without this information if not available. However, using this information, the nomogram can provide more refined predictions. min: >=0; max: <=20 |
| Negative biopsy cores | Negative biopsy cores: Number of negative cores taken during biopsy. Information on cores taken at biopsy is optional. The nomogram can provide predictions without this information if not available. However, using this information, the nomogram can provide more refined predictions. min: >=0; max: <=20 |
| Percentage positive | Percentage positive: What percentage of the biopsy samples taken were positive?
Assumed value: false |
| Probability 10-year survival | Probability 10-year survival: Probability of cancer-specific survival for 10 years after radical prostatectomy.
Assumed value: false |
| Probability 15-year survival | Probability 15-year survival: Probability of cancer-specific survival for 15 years after radical prostatectomy.
Assumed value: false |
| Progression free probability 5 years | Progression free probability 5 years: Progression-free probability for 5 years after radical prostatectomy.
Assumed value: false |
| Progression free probability 10 years | Progression free probability 10 years: Progression-free probability for 10 years after radical prostatectomy.
Assumed value: false |
| Organ-confined disease probability | Organ-confined disease probability: This number shows, as a percentage, the probability that the cancer will be found to be confined to the prostate gland when the prostate is removed.
Assumed value: false |
| Extra-capsular extension probability | Extra-capsular extension probability: This number shows, as a percentage, the probability of “extracapsular extension,” meaning the probability that the cancer extends through the capsule of the prostate into the surrounding tissue.
Assumed value: false |
| Lymph node involvement probability | Lymph node involvement probability: This number shows, as a percentage, the probability that prostate cancer has spread to the pelvic lymph nodes.
Assumed value: false |
| Seminal invasion probability | Seminal invasion probability: This number shows, as a percentage, the probability of “seminal vesicle invasion,” which occurs when prostate cancer has spread into the seminal vesicles — glands attached to the prostate that help to produce semen. This number shows the probability that the cancer has spread to one or both seminal vesicles.
Assumed value: false |
| events | |
| Point in time | Point in time: A specific date and/or time which may be explicitly defined in a template or at run-time. |
| Other contributors | |
| Translators |